Opinion|Videos|October 9, 2024
Integrating Support Services and Caregiver Roles in mCRC Care
Key Takeaways
- Patients in the third-line stage of mCRC experience anxiety, fear, and uncertainty, impacting treatment decision-making.
- Early involvement of support services, such as social work and palliative care, is crucial for addressing psychosocial challenges.
Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- To set the stage, what are some of the psychological and emotional aspects of treatment decision-making with patients entering the third-line stage of metastatic colorectal cancer?
- What are your recommendations for involving support services (such as social work or palliative care) to help patients navigate the psychosocial components of metastatic colorectal cancer (mCRC), and at what point in a patient’s care journey does this begin?
- What is the role of the caregiver in advanced mCRC in supporting a patient through these psychosocial components?
Advertisement
Related to this article
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
4
International Panel Agrees on Framework for Tapering Psoriasis Biologics
5